ERC Worldwide today announced the launch of the Company’s development program for its therapeutic and prophylactic vaccine against the new coronavirus SARS-CoV-2. The technology is based on ERC’s Gliovac/ERC1671 glioblastoma vaccine platform currently in an FDA approved clinical trial in the US.